S&P Biotech SPDR (XBI): Congress and insider trades
Who in Congress and inside the company traded XBI, when each filing appeared, and what buying after each one would have earned against the S&P 500.
Key Facts
- S&P Biotech SPDR (XBI) is a listed stock on AMEX.
- 1 member of Congress filed 1 buy and 0 sells of XBI, the latest published 2026-08-05 (5 August 2026).
- Data as of 2026-09-29 (29 September 2026).
Congress trades in XBI
as of 2026-08-05| Filed | Member | Type | Size | Days to file | 90 day vs S&P |
|---|---|---|---|---|---|
| 5 Aug 2026 | Tommy Tuberville (R-AL) | buy | 1Kâ15K | 819 | n/a |
Nothing matches that search.
Related pages
Frequently asked questions
Who has bought XBI?
1 Congress buy by 1 member and 0 insider buys are on file. The tables on this page list every one.
Did buying XBI after a disclosure beat the market?
No disclosed buy of this stock has matured 90 days yet. A single stock is a small sample.
Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.
Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.